MiR-218-5p/EGFR Signaling in Arsenic-Induced Carcinogenesis

Simple Summary EGFR upregulation plays an important role in lung cancer as a well-established target for lung cancer therapy. However, the role and mechanism of EGFR upregulation due to chronic arsenic exposure remain to be elucidated. Here, we demonstrated that miR-218-5p was dramatically downregulated in arsenic-induced transformed (As-T) cells. It served as a tumor suppressor to suppress cell proliferation, migration, colony formation, and tube formation, and inhibit tumor growth and angiogenesis by directly targeting EGFR. Our results suggest that the 218-5p/EGFR signaling pathway may be a potential therapeutic target for the treatment of lung cancer induced by chronic arsenic exposure. Abstract Background: Arsenic is a well-known carcinogen inducing lung, skin, bladder, and liver cancer. Abnormal epidermal growth factor receptor (EGFR) expression is common in lung cancer; it is involved in cancer initiation, development, metastasis, and treatment resistance. However, the underlying mechanism for arsenic-inducing EGFR upregulation remains unclear. Methods: RT-PCR and immunoblotting assays were used to detect the levels of miR-218-5p and EGFR expression. The Luciferase assay was used to test the transcriptional activity of EGFR mediated by miR-218-5p. Cell proliferation, colony formation, wound healing, migration assays, tube formation assays, and tumor growth assays were used to study the function of miR-218-5p/EGFR signaling. Results: EGFR and miR-218-5p were dramatically upregulated and downregulated in arsenic-induced transformed (As-T) cells, respectively. MiR-218-5p acted as a tumor suppressor to inhibit cell proliferation, migration, colony formation, tube formation, tumor growth, and angiogenesis. Furthermore, miR-218-5p directly targeted EGFR by binding to its 3′-untranslated region (UTR). Finally, miR-218-5p exerted its antitumor effect by inhibiting its direct target, EGFR. Conclusion: Our study highlights the vital role of the miR-218-5p/EGFR signaling pathway in arsenic-induced carcinogenesis and angiogenesis, which may be helpful for the treatment of lung cancer induced by chronic arsenic exposure in the future.

[1]  Y. Wang,et al.  Epigenetic Regulation in Chromium-, Nickel- and Cadmium-Induced Carcinogenesis , 2022, Cancers.

[2]  G. Lu-Yao,et al.  Epigenetic Dysregulations in Arsenic-Induced Carcinogenesis , 2022, Cancers.

[3]  A. Farooqi,et al.  Non-small-cell lung cancer: how to manage EGFR-mutated disease , 2022, Drugs in context.

[4]  Gang Chen,et al.  MicroRNA-218-5p affects lung adenocarcinoma progression through targeting endoplasmic reticulum oxidoreductase 1 alpha , 2022, Bioengineered.

[5]  B. Jiang,et al.  Human endothelial cells promote arsenic-transformed lung epithelial cells to induce tumor growth and angiogenesis through interleukin-8 induction , 2022, Aging.

[6]  Hushan Yang,et al.  Redox sensitive miR-27a/b/Nrf2 signaling in Cr(VI)-induced carcinogenesis. , 2021, The Science of the total environment.

[7]  T. Kalbfleisch,et al.  Dynamic alteration in miRNA and mRNA expression profiles at different stages of chronic arsenic exposure-induced carcinogenesis in a human cell culture model of skin cancer , 2021, Archives of Toxicology.

[8]  B. Jiang,et al.  HB-EGF Activates the EGFR/HIF-1α Pathway to Induce Proliferation of Arsenic-Transformed Cells and Tumor Growth , 2020, Frontiers in Oncology.

[9]  J. States,et al.  Chronic and acute arsenic exposure enhance EGFR expression via distinct molecular mechanisms. , 2020, Toxicology in vitro : an international journal published in association with BIBRA.

[10]  M. Martínez-Castillo,et al.  Arsenic exposure: A public health problem leading to several cancers. , 2019, Regulatory toxicology and pharmacology : RTP.

[11]  Yan-wei Liu,et al.  Survivin is a prognostic indicator in glioblastoma and may be a target of microRNA-218. , 2019, Oncology letters.

[12]  Xiao Luo,et al.  Long non-coding RNA MNX1-AS1 promotes hepatocellular carcinoma proliferation and invasion through targeting miR-218-5p/COMMD8 axis. , 2019, Biochemical and biophysical research communications.

[13]  Xiaoqiang Sun,et al.  Multiscale modeling reveals angiogenesis-induced drug resistance in brain tumors and predicts a synergistic drug combination targeting EGFR and VEGFR pathways , 2019, BMC Bioinform..

[14]  Bei Sun,et al.  MicroRNA‐218–5p inhibit the migration and proliferation of pterygium epithelial cells by targeting EGFR via PI3K/Akt/mTOR signaling pathway , 2019, Experimental eye research.

[15]  S. Rai,et al.  miRNA expression profiles of premalignant and malignant arsenic-induced skin lesions , 2018, PloS one.

[16]  Sharon L. Qi,et al.  Estimating the High-Arsenic Domestic-Well Population in the Conterminous United States. , 2017, Environmental science & technology.

[17]  Chao Zeng,et al.  miR-218 suppresses gastric cancer cell cycle progression through the CDK6/Cyclin D1/E2F1 axis in a feedback loop. , 2017, Cancer letters.

[18]  M. Fang,et al.  Hypoxia-inducible microRNA-218 inhibits trophoblast invasion by targeting LASP1: Implications for preeclampsia development. , 2017, The international journal of biochemistry & cell biology.

[19]  Hongbing Shen,et al.  Downregulation of miR-218 contributes to epithelial–mesenchymal transition and tumor metastasis in lung cancer by targeting Slug/ZEB2 signaling , 2017, Oncogene.

[20]  Peng Guo,et al.  Tumor-suppressive microRNA-218 inhibits tumor angiogenesis via targeting the mTOR component RICTOR in prostate cancer , 2016, Oncotarget.

[21]  Shu Fang,et al.  Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts , 2016, Oncotarget.

[22]  F. Ciardiello,et al.  Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence , 2016, ESMO Open.

[23]  C. Su,et al.  Tanshinone IIA decreases the protein expression of EGFR, and IGFR blocking the PI3K/Akt/mTOR pathway in gastric carcinoma AGS cells both in vitro and in vivo. , 2016, Oncology reports.

[24]  X. Chen,et al.  Tumor-suppressive miR-218-5p inhibits cancer cell proliferation and migration via EGFR in non-small cell lung cancer , 2016, Oncotarget.

[25]  M. El-Shinawi,et al.  Secretome of tumor-associated leukocytes augment epithelial-mesenchymal transition in positive lymph node breast cancer patients via activation of EGFR/Tyr845 and NF-κB/p65 signaling pathway , 2016, Tumor Biology.

[26]  Agustina Briatore,et al.  Epidemiology of chronic disease related to arsenic in Argentina: A systematic review. , 2015, The Science of the total environment.

[27]  P. Zarogoulidis,et al.  MiR-205 and miR-218 expression is associated with carboplatin chemoresistance and regulation of apoptosis via Mcl-1 and Survivin in lung cancer cells. , 2015, Cellular signalling.

[28]  W. Cho,et al.  Emerging Roles of MicroRNAs in EGFR-Targeted Therapies for Lung Cancer , 2015, BioMed research international.

[29]  X. Yang,et al.  MicroRNA-218 inhibits bladder cancer cell proliferation, migration, and invasion by targeting BMI-1 , 2015, Tumor Biology.

[30]  Janice Ortega,et al.  Arsenic Inhibits DNA Mismatch Repair by Promoting EGFR Expression and PCNA Phosphorylation* , 2015, The Journal of Biological Chemistry.

[31]  F. Cheng,et al.  Pyruvate kinase M2 affects liver cancer cell behavior through up-regulation of HIF-1α and Bcl-xL in culture. , 2015, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[32]  Susan R. Quinn,et al.  Pyruvate kinase M2 regulates Hif-1α activity and IL-1β induction and is a critical determinant of the warburg effect in LPS-activated macrophages. , 2015, Cell metabolism.

[33]  Susan R. Quinn,et al.  Pyruvate Kinase M2 Regulates Hif-1α Activity and IL-1β Induction and Is a Critical Determinant of the Warburg Effect in LPS-Activated Macrophages. , 2015, Cell metabolism.

[34]  Feng Xie,et al.  Overexpression of miR-218 inhibits hepatocellular carcinoma cell growth through RET , 2015, Tumor Biology.

[35]  W. Pavan,et al.  Distinct microRNA expression signatures are associated with melanoma subtypes and are regulated by HIF1A , 2014, Pigment cell & melanoma research.

[36]  S. Grando,et al.  Connections of nicotine to cancer , 2014, Nature Reviews Cancer.

[37]  Qing Xu,et al.  Chronic Arsenic Exposure and Angiogenesis in Human Bronchial Epithelial Cells via the ROS/miR-199a-5p/HIF-1α/COX-2 Pathway , 2014, Environmental health perspectives.

[38]  K. Aldape,et al.  EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis. , 2012, Molecular cell.

[39]  K. Aldape,et al.  ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect , 2012, Nature Cell Biology.

[40]  K. Aldape,et al.  PKM2 Phosphorylates Histone H3 and Promotes Gene Transcription and Tumorigenesis , 2012, Cell.

[41]  R. Bamezai,et al.  Resveratrol Inhibits Cancer Cell Metabolism by Down Regulating Pyruvate Kinase M2 via Inhibition of Mammalian Target of Rapamycin , 2012, PloS one.

[42]  Xueliang Gao,et al.  Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. , 2012, Molecular cell.

[43]  K. Aldape,et al.  Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation , 2011, Nature.

[44]  Y. Rojanasakul,et al.  Arsenite induces cell transformation by reactive oxygen species, AKT, ERK1/2, and p70S6K1. , 2011, Biochemical and biophysical research communications.

[45]  Zhengyu Zha,et al.  Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. , 2011, Molecular cell.

[46]  Matthew K. Knabel,et al.  Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1 , 2011, Cell.

[47]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[48]  Ya‐Wen Cheng,et al.  Paxillin predicts survival and relapse in non-small cell lung cancer by microRNA-218 targeting. , 2010, Cancer research.

[49]  R. Bamezai,et al.  Human pyruvate kinase M2: A multifunctional protein , 2010, Protein science : a publication of the Protein Society.

[50]  Nazmul Sohel,et al.  Arsenic in Drinking Water and Adult Mortality: A Population-based Cohort Study in Rural Bangladesh , 2009, Epidemiology.

[51]  Kurt Straif,et al.  A review of human carcinogens--Part C: metals, arsenic, dusts, and fibres. , 2009, The Lancet. Oncology.

[52]  A. Andrew,et al.  Arsenic Activates EGFR Pathway Signaling in the Lung , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[53]  G. Weiss,et al.  MicroRNAs and cancer: past, present, and potential future , 2008, Molecular Cancer Therapeutics.

[54]  R. Weinberg,et al.  Micromanagers of malignancy: role of microRNAs in regulating metastasis. , 2008, Trends in genetics : TIG.

[55]  Ru Wei,et al.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth , 2008, Nature.

[56]  M. Vahter.  Health effects of early life exposure to arsenic. , 2008, Basic & clinical pharmacology & toxicology.

[57]  G. Tortora,et al.  Rational bases for the development of EGFR inhibitors for cancer treatment. , 2007, The international journal of biochemistry & cell biology.

[58]  M. Bates,et al.  Fifty-year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water. , 2007, Journal of the National Cancer Institute.

[59]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[60]  E. Miska,et al.  How microRNAs control cell division, differentiation and death. , 2005, Current opinion in genetics & development.

[61]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[62]  I. Jaspers,et al.  Differential activation of AP‐1 in human bladder epithelial cells by inorganic and methylated arsenicals , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[63]  J. Baselga,et al.  Targeting epidermal growth factor receptor in lung cancer , 2002, Current oncology reports.

[64]  M. Burchardt,et al.  Tumor hypoxia and the progression of prostate cancer , 2002, Current urology reports.

[65]  E. Lai.  Micro RNAs are complementary to 3′ UTR sequence motifs that mediate negative post-transcriptional regulation , 2002, Nature Genetics.

[66]  F. Hirsch,et al.  Epidermal growth factor receptor family in lung cancer and premalignancy. , 2002, Seminars in oncology.

[67]  M. Luster,et al.  c-Src-dependent Activation of the Epidermal Growth Factor Receptor and Mitogen-activated Protein Kinase Pathway by Arsenic , 2002, The Journal of Biological Chemistry.

[68]  V. Ambros.  microRNAs Tiny Regulators with Great Potential , 2001, Cell.

[69]  V. Ambros,et al.  An Extensive Class of Small RNAs in Caenorhabditis elegans , 2001, Science.

[70]  G. Semenza,et al.  Hypoxia, Clonal Selection, and the Role of HIF-1 in Tumor Progression , 2000, Critical reviews in biochemistry and molecular biology.

[71]  H. Swartz,et al.  Stimulation of reactive oxygen, but not reactive nitrogen species, in vascular endothelial cells exposed to low levels of arsenite. , 1999, Free radical biology & medicine.

[72]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[73]  Jessica Lo,et al.  HIF‐1α is required for solid tumor formation and embryonic vascularization , 1998 .

[74]  G. Semenza,et al.  V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. , 1997, Cancer research.

[75]  A. Harris,et al.  Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[76]  C. Hopenhayn-Rich,et al.  Bladder Cancer Mortality Associated with Arsenic in Drinking Water in Argentina , 1996, Epidemiology.

[77]  A. Smith,et al.  Cancer risks from arsenic in drinking water. , 1992, Environmental health perspectives.

[78]  T. Kuo,et al.  ARSENIC AND CANCERS , 1988, The Lancet.

[79]  J. Fraumeni,et al.  ARSENICAL AIR POLLUTION AND LUNG CANCER , 1975, The Lancet.

[80]  H. S. Satterlee.  The arsenic-poisoning epidemic of 1900. Its relation to lung cancer in 1960 - an exercise in retrospective epidemiology. , 1960, The New England journal of medicine.